Wall Street Analysts Believe Collegium Pharmaceutical (COLL) Could Rally 81.63%: Here's is How to TradeZacks Investment Research • Tuesday
Collegium Pharmaceutical (COLL) Tops Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/05/26
Compared to Estimates, Collegium Pharmaceutical (COLL) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 11/05/26
Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 GuidanceGlobeNewsWire • 11/05/26
Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to DeclineZacks Investment Research • 10/29/26
Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across MassachusettsGlobeNewsWire • 10/29/26
Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall CongressesGlobeNewsWire • 10/21/26
Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?Zacks Investment Research • 10/16/26
Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday LifeGlobeNewsWire • 10/06/26
Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/16/26
Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 08/06/26
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/06/26
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 08/06/26